U.S. Oxygen Concentrator Market (2025 - 2033)

U.S. Oxygen Concentrator Market Summary

The U.S. oxygen concentrator market size was estimated at USD 1.55 billion in 2024 and is projected to reach USD 3.09 billion by 2033, growing at a CAGR of 7.6% from 2025 to 2033. The increase in the prevalence of respiratory conditions such as COPD, asthma, and sleep apnea, rising healthcare spending, significant investment in R&D, advanced healthcare infrastructure, access to the newest technology, and new product launches.

According to the analyzed Medicare claims data, the Medicare penetration rate for portable oxygen concentrators (POCs) in the U.S. has steadily risen. For instance, in 2021, the POC penetration was 22.0%, while that of stationary was 17%. This is a developing trend favoring portable oxygen concentrators (POCs) over fixed oxygen concentrators and fueling the expansion of the U.S. oxygen concentrator industry.

Government support, such as the Federal Aviation Administration's (FAA) approval of portable concentrators during plane travel, further drives the region's growth. Furthermore, favorable reimbursement policies have enhanced the attractiveness of the U.S. oxygen concentrators market. For instance, in March 2024, a U.S. Congressman introduced the Supplemental Oxygen Access Reform (SOAR) Act to reform and improve access to supplementary oxygen for Medicare beneficiaries. These policies have increased the adoption of oxygen concentrators in the U.S. In addition, rising healthcare spending in the U.S. is driving the demand for effective diagnosis and treatment of respiratory diseases, thereby boosting the market for oxygen concentrators.

The rising prevalence of chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), is a key driver of the U.S. oxygen concentrator market. With COPD affecting over 5% of U.S. adults and contributing to nearly USD 50 billion in annual economic costs, the demand for effective oxygen therapy solutions continues to grow. Long-term oxygen therapy has been clinically proven to improve outcomes in hypoxemic patients, making oxygen concentrators an essential part of disease management.

Moreover, limitations of traditional oxygen delivery methods, such as stationary systems and oxygen cylinders that restrict mobility and require frequent refills, accelerate the shift toward portable oxygen concentrators. These devices provide patients with greater independence and flexibility while addressing the increasing burden of COPD, cystic fibrosis, and heart failure-related hypoxemia, thereby fueling adoption across the U.S. market.

Market Concentration & Characteristics

The chart below illustrates the relationship between market concentration, industry characteristics, and industry participants. The x-axis represents the level of industry concentration, ranging from low to high. The y-axis represents various industry characteristics, including industry competition, impact of regulations, level of partnerships & collaborations activities, degree of innovation, and regional expansion. For instance, the U.S. oxygen concentrator market is slightly fragmented, with many product & service providers entering the market. The degree of innovation, the level of partnerships & collaboration activities, and the impact of regulations on the industry is high.

The degree of innovation in the industry is high. The market is experiencing significant innovation as companies like Inogen are introducing cutting-edge products. For instance, in December 2022, Inogen U.S.-based company, received 510(k) premarket clearance from the U.S. Food and Drug Administration (FDA) for its new portable oxygen concentrator, Rove 4. This product is expected to enhance Inogen's leadership in portable oxygen concentrators. Such regulatory milestones strengthen manufacturers' portfolios, as seen with Inogen's Rove series.

M&A activities like mergers, acquisitions, and partnerships facilitate geographic expansion and market entry for companies. For example, React Health, a player in medical device development, manufacturing, and distribution, acquired Invacare's Respiratory line in February 2023. This strategic move bolsters React Health's market standing, broadens its product offerings, and enhances its ability to serve a wider customer base.

“The addition of the Invacare product line to React Health’s Respiratory offering further strengthens our commitment to providing a full complement of products and services to treat chronic disease states in the home setting. We look forward to welcoming Invacare’s customers and patients to the React Health family.”

-Clint Geffert, President of Commercial Operations at React Health

The impact of regulations on the U.S. oxygen concentrator market is high. The market is significantly influenced by various regulations, which play a critical role in shaping the growth, innovation, and operational processes of oxygen concentrators. The regulatory framework for oxygen concentrators represents a significant barrier, particularly in terms of regulatory stringency. Companies such as Invacare Corporation and Philips have encountered prolonged consent decrees from the U.S. FDA, illustrating the stringent regulatory environment in the U.S. market.

The level of regional expansion in the U.S. oxygen concentrator industry is moderate. Increasing demand for oxygen concentrators in the U.S., owing to fostering collaboration, access to diverse datasets, and talent pools across regions. It enables companies to tap into new markets, leverage local expertise, comply with region-specific regulations, and gain insights from different healthcare systems, ultimately driving innovation and accelerating the adoption of oxygen concentrators.

Case Study:

In October 2024, RespoCare published a case study titled “Freedom with Portable Oxygen”.

Product Insights

The fixed concentrators segment led the U.S. oxygen concentrator market with the largest revenue market share of 46.8% in 2024. Factors such as a higher oxygen output capacity, cost-effectiveness, and widespread adoption in home healthcare settings. Their ability to deliver continuous oxygen flow for patients with chronic respiratory conditions makes them the preferred choice, especially for long-term therapy, contributing to their dominant market share.

The portable oxygen concentrators (POCs) segment is anticipated to witness the fastest CAGR over the forecast period owing to the increasing need for portable medical oxygen concentrators, especially among mobile patients seeking out-of-home solutions. Companies are actively pursuing opportunities to expand in this market segment. For instance, in June 2022, Carire launched a new portable oxygen concentrator, LifeStyle, in the U.S. market. This product has substantially improved the quality of life for oxygen users worldwide by providing a more convenient and reliable oxygen source.

Application Insights

The home care segment led the U.S. oxygen concentrator industry with the largest revenue share in 2024. The home care segment is projected to experience the fastest CAGR during the forecast period. The growth can be attributed to the rising adoption of Long-Term Oxygen Therapy (LTOT) devices in home settings, the availability of a wide range of home oxygen therapy devices (including Liquid Oxygen systems and portable concentrators), and the shifting preferences of patients towards receiving treatment at home.

The non-homecare segment is expected to exhibit a moderate CAGR over the forecast period. The growth of the segment is driven by the increased adoption of oxygen therapy in hospitals and clinics. Moreover, an increasing number of hospital admissions due to respiratory diseases contributes to the segment’s growth.

Technology Insights

The continuous flow segment led the U.S. oxygen concentrator market with the largest revenue share of 56.03% in 2024. This segment's dominance can be attributed to the increasing prevalence of long-term respiratory disorders, including asthma, COPD, bronchiectasis, and chronic sinusitis. Continuous flow technology is also widely used in residential and military applications, providing a safer alternative to storing oxygen under pressure.

The pulse flow technology segment is expected to experience the fastest CAGR during the forecast period. The growth is driven by the advantages offered by pulse flow technology, including high mobility, lightweight design, and suitability for patients with active lifestyles. Pulse flow technology is particularly beneficial for treating respiratory conditions that require a lower oxygen delivery rate per minute. It is extensively used in portable oxygen concentrators (POCs).

Key U.S. Oxygen Concentrator Company Insights

The U.S. oxygen concentrators industry is highly competitive, with Inogen as a notable player in the portable oxygen category, holding a dominant position. It competes with both portable oxygen concentrator manufacturers and long-term oxygen therapy providers, such as Respironics (a subsidiary of Koninklijke Philips N.V.), React Health (Respiratory Product Line from Invacare Corporation), Caire Medical (a subsidiary of NGK Spark Plug), and DeVilbiss Healthcare (a subsidiary of Drive Medical).

Comparison Matrix: U.S. Oxygen Concentrator Market: Company-wise Market Share, Value & Unit Volume Trends (2021 - 2024)

Exit Strategies of Existing Market Players And Their Impact On Market Competitors

Invacare's exit strategy aims to realign the company with its mission and vision.

• Invacare Corporation has announced its decision to discontinue its respiratory products line, including HomeFill and stationary & portable oxygen concentrators.

• This strategic move, disclosed alongside the company's third-quarter financial results of 2022, highlights Invacare's commitment to taking decisive action to enhance shareholder value and accelerate the execution of its strategic plan.

• Following an extensive review process lasting almost a year, the decision demonstrates the company's acknowledgment of unfavorable market conditions.

Entry Of React Health Following Invacare's Exit And Its Anticipated Impact

• The acquisition of Invacare's respiratory assets by React Health is likely to have significant implications for the oxygen concentrator market, including changes in competition, product availability, market dynamics, customer support, etc.

Recent Developments

• In January 2025, Caire launched IntenOxy 5, a stationary oxygen concentrator in the U.S. and Puerto Rico. This delivers around 95.5% oxygen concentration and operates efficiently with low power consumption.

“The IntenOxy 5 Stationary Oxygen Concentrator has been an excellent addition to our oxygen therapy portfolio. The unit is a key component to how our DME and HME customers serve their respiratory patients, providing them with an at-home device that delivers the oxygen they need as they navigate activities of daily living,”

-Ken Hosako, president and CEO of Caire.

• In July 2023, VARON launched a new portable oxygen concentrator, VP-2, to the VP series of the company. This concentrator aims to provide efficient and reliable oxygen therapy regardless of their location.

Our goal is to make oxygen therapy more accessible by providing reliable, efficient, and affordable solutions for anyone in need. With VP-2 coming out, we believe we are much closer to the goal."

- Darren Wang, CEO of VARON

• In July 2023, Canta Medical introduced an entire oxygen product range to the FIME 2023 United States. FIME 2023 is one of the largest international medical exhibitions for the U.S. healthcare market. It attracts over 10,000 healthcare participants and hosts over 500 medical device manufacturers and distributors

• In April 2022, CAIRE launched LifeStyle, a portable oxygen concentrator for improving the quality of life for oxygen concentrator uses.

“Pioneering the first portable oxygen concentrator has long been both a point of pride, and an ongoing incentive to continue to innovate and develop those technologies that will ensure clinically efficacious oxygen delivery and an improved quality of life for all of our users around the world,”

-said Earl Lawson, CEO of CAIRE Inc.

U.S. Oxygen Concentrator Market